It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
The emergence of newer SARS-CoV-2 variants of concern (VOCs) profoundly changed the ICU demography; this shift in the virus’s genotype and its correlation to lethality in the ICUs is still not fully investigated. We aimed to survey ICU patients’ clinical and laboratory parameters in correlation with SARS-CoV-2 variant genotypes to lethality. 503 COVID-19 ICU patients were included in our study beginning in January 2021 through November 2022 in Hungary. Furthermore, we implemented random forest (RF) as a potential predictor regarding SARS-CoV-2 lethality among 649 ICU patients in two ICU centers. Survival analysis and comparison of hypertension (HT), diabetes mellitus (DM), and vaccination effects were conducted. Logistic regression identified DM as a significant mortality risk factor (OR: 1.55, 95% CI 1.06–2.29, p = 0.025), while HT showed marginal significance. Additionally, vaccination demonstrated protection against mortality (p = 0.028). RF detected lethality with 81.42% accuracy (95% CI 73.01–88.11%, [AUC]: 91.6%), key predictors being PaO2/FiO2 ratio, lymphocyte count, and chest Computed Tomography Severity Score (CTSS). Although a smaller number of patients require ICU treatment among Omicron cases, the likelihood of survival has not proportionately increased for those who are admitted to the ICU. In conclusion, our RF model supports more effective clinical decision-making among ICU COVID-19 patients.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 University of Pécs, Department of Laboratory Medicine, Medical School, Pécs, Hungary (GRID:grid.9679.1) (ISNI:0000 0001 0663 9479); University of Pécs, Molecular Medicine Research Group, Szentágothai Research Centre, Pécs, Hungary (GRID:grid.9679.1) (ISNI:0000 0001 0663 9479)
2 University of Pécs, Molecular Medicine Research Group, Szentágothai Research Centre, Pécs, Hungary (GRID:grid.9679.1) (ISNI:0000 0001 0663 9479)
3 University of Pécs, Molecular Medicine Research Group, Szentágothai Research Centre, Pécs, Hungary (GRID:grid.9679.1) (ISNI:0000 0001 0663 9479); University of Debrecen, Institute of Metagenomics, Debrecen, Hungary (GRID:grid.7122.6) (ISNI:0000 0001 1088 8582)
4 University of Debrecen, Department of Anaesthesiology and Intensive Care, Debrecen, Hungary (GRID:grid.7122.6) (ISNI:0000 0001 1088 8582)
5 University of Debrecen, Doctoral School of Neuroscience, Debrecen, Hungary (GRID:grid.7122.6) (ISNI:0000 0001 1088 8582)
6 University of Debrecen, Institute of Forensic Medicine, Debrecen, Hungary (GRID:grid.7122.6) (ISNI:0000 0001 1088 8582)
7 University of Pécs, Department of Anaesthesiology and Intensive Care, Clinical Centre, Pécs, Hungary (GRID:grid.9679.1) (ISNI:0000 0001 0663 9479)